1.
R Soc Open Sci
; 6(6): 190338, 2019 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31312496
RESUMO
HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from N É -acetyl lysine. In the current study, we raised a novel design, which concerns N É -acetyl lysine derivatives containing amide acetyl groups with the hybridization of ZBG groups as novel HDAC inhibitors.